



### Demographics and socioeconomic

Total Population (in 1000) (2020)	19,116.21
Population <1 year of age (in 1000) (2020)	214.01
Population 1 year of age (in 1000) (2020)	225.34
Population <5 years of age (in 1000) (2020)	1,162.22
Women of childbearing age (in 1000) (2020)	13,441.30
Infant Mortality Rate (per 1000 live births) (2017)	7.1
Gross national income (US\$ per capita) current value (2020)	13,470.0
National Health Expenditure Public (2018)	4.6
National Health Expenditure Private (2018)	4.5

### Immunization system highlights

- There is a comprehensive multi-year plan for immunization covering 2020-2021.
- A standing national technical advisory group on immunization (NITAG) with formal written terms of reference exists. The group met 12 times in 2020.
- No information is available on spending on routine immunization financed using government funds.
- No information is available on spending on vaccine purchase financed using government funds.
- A national nominal electronic immunization registry is in place.


### Vaccine Introduction

	Year
Bacterial Meningitis	
<i>Haemophilus influenzae</i> type b	1996
Hepatitis B	2005
HPV	2014
Influenza	1975
MMR1	1990
MMR2	1992
Pentavalent	2006
Pneumococcal Conjugate	2011
Rotavirus	
Tdap	
Tetavalent DPT-Hib or DPT-HepB	1996
Yellow Fever	

### Immunization Schedule

	Doses					
CHL	1	2	3	4	5	6
BCG	B					
HepB pediatric	B					
DTP-Hib						
DTP-Hib-HepB						
DTP-Hib-IPV						
DTP-Hib-HepB-IPV	M2	M4	M6	M18		
DTP						
Influenza pediatric	M6-Y5	Y6-Y10				
IPV						
OPV						
MMR	Y1	Y6				
Pneumoco conjugate	M2	M4	M6			
Rotavirus						
Td						
Tdap	Y6	Y13				
HPV						

### Vaccination Coverage




### Surveillance indicators

Acute flaccid paralysis (AFP)	2020
Number of AFP suspected cases	41
AFP rate per 100,000 population <15 years old	1.11
% of cases with 1 adequate samples	66
% of cases investigated within <48 hours	71
% sites reporting	47


Measles-rubella (MR)	2020
Number of MR suspected cases	49
% of cases with adequate investigation	8
% of cases with adequate blood samples	96
% of samples received in laboratory <=5 days	87
% of laboratory samples results <=4 days	94




### Polio3 coverage and AFP rate per 100,000 children <15 years of age




### DTP3 coverage and number of reported diphtheria and pertussis cases




### Number of tetanus (no neonatal) and neonatal tetanus cases



### Proportion of municipalities by coverage range with DTP3 in children <1 years of age



### DTP1-DTP3 and DTP1-MMR1 Dropout Rate



**Legend**  
 NB/nb-newborn  
 M/m -month  
 Y/y-year  
 WCBA-women of childbearing age  
 ● with stockout  
 ● no stockout  
 no data available

### Vaccine Stockout

CHL	2013	2014	2015	2016	2017	2018	2019	2020
AD syringes								
BCG	●	●	●	●	●	●	●	●
Disposable syringes	●	●	●	●	●	●	●	●
DTP	●	●	●	●	●	●	●	●
HepB	●	●	●	●	●	●	●	●
Hib	●	●	●	●	●	●	●	●
Influenza	●	●	●	●	●	●	●	●
IPV			●	●	●	●	●	●
Measles	●	●	●	●	●	●	●	●
Pneumo. conjugate	●	●	●	●	●	●	●	●
Polio	●	●	●	●	●	●	●	●
Reconst. syringes	●		●	●	●		●	●
Rotavirus			●					
Safety boxes	●	●	●	●	●	●	●	●
Tdap		●	●	●	●	●	●	●
TT	●	●	●	●	●	●	●	●
Yellow fever	●	●	●			●	●	●